Oprelvekin and Renal impairment
Result of checking the interaction of drug Oprelvekin and disease Renal impairment for safety when used together.
When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.
Consumer:Oprelvekin is primarily eliminated by the kidneys and drug exposure was significantly increased in patients with severe renal impairment (CrCl <30 mL/min). The recommended dose in these patients is 50 mcg/kg once a day. No significant changes were observed in patients with mild or moderate impairment. Fluid retention associated with oprelvekin has not been studied in patients with renal impairment, but fluid balance should be carefully monitored in these patients.